Pre Therapy Patient Dosimetry with ¹⁷⁷Lu-PSMA CC34 Indonesia Experience

Based on WHO data in 2014, prostate cancer in Indonesia has been ranked as the 3rd place after lung and colorectal cancers. In the last few years, the management of prostate cancer in nuclear medicine in Indonesia has been evolved in diagnostic procedures. According to some references, ¹⁷⁷Lu has been used for theranostic procedures because it can be utilized as diagnosis and therapy agent. In addition, several clinical evaluations of ¹⁷⁷Lu-PSMA have been carried out worldwide and the results have been satisfactory in prostate cancer patients. The individualized patient dosimetry in Radionuclide Therapy also has been considering as a global issue since the Bonn Call for Action in 2012 has stated that patient dosimetry in Radionuclide Therapy should be more developed to consider radiation protection of patient who undergo therapy using unsealed radionuclide (Radionuclide Therapy, RNT). Nevertheless, the implementation of dosimetry in RNT in Indonesia has not been applied before 2017. Hence, considering the benefits, Indonesia has initiated a pre therapy dosimetry study for prostate cancer patient who will be treated using ¹⁷⁷Lu-PSMA in the mid of 2017 with the support from IAEA-CRP E230005 "Dosimetry in Molecular Radiotherapy for Personalized Patient Treatments. The study is aimed to perform pre therapy dosimetry and investigate the radiation dose to kidney and liver as critical organs in radionuclide therapy using ¹⁷⁷Lu-PSMA, and establish the protocol for performing patient dosimetry for patients in radionuclide therapy in Indonesia.